Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Starbreeze AB (publ) including five Swedish subsidiaries have today filed for reconstruction

STOCKHOLM (3 December 2018) – Starbreeze AB (publ) (“Starbreeze” or the “Company”) announces that the board of Starbreeze AB (publ) and the boards of the Company’s Swedish subsidiaries Starbreeze Publishing, Starbreeze Production, Starbreeze Studios, Enterspace and Enterspace International, have today filed for reconstruction with the Stockholm District Court. The decision is based on a shortage of liquidity and deemed to be a necessary step to give the Company the time needed to negotiate a long-term financial solution and implement changes in the organization and operations. The financial

Starbreeze board of directors resolves to replace the CEO

STOCKHOLM (3 December 2018) – The board of directors and Bo Andersson have today agreed that Andersson will step down as CEO of Starbreeze. The board of directors has appointed the Deputy CEO Mikael Nermark as Acting CEO. Bo Andersson and Kristofer Arwin have further resigned from Starbreeze Board of Directors effective immediately.  As communicated today the board has filed for reconstruction and as communicated on 23 November 2018, the board of directors has mandated executive management to review operation and the company has initiated a program to lower costs and focus on its core

Saga Tankers ASA : EX DIVIDEND NOK 0.15 TODAY

Key information relating to the cash dividend to be paid by Saga Tankers ASA   Dividend amount: NOK 0.15 per share.   Declared currency: NOK   Last day including right: 30 November 2018   Ex-date: 3 December 2018   Record Date: 4 December 2018   Payment Date: 10 December 2018   Date of approval: 30 November 2018      * * *   For further information, please contact: CEO Espen Lundaas   +47 92 43 14 17 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

myFC’s fuel cell charger JAQ Hybrid receives Japanese PSE certification

The world’s smallest fuel cell charger, JAQ Hybrid, is now PSE certified under the Electrical Appliance and Material Safety Law (DENAN), established by Japan’s Ministry of Economy, Trade and Industry (METI).Starting February 1, 2019, the Japanese PSE certification requirement is extended to include power banks and other products such as JAQ Hybrid. myFC can today confirm that JAQ Hybrid has passed PSE conformance testing with a registered conformity assessment body, and that the PSE Circle Mark will be affixed on JAQ Hybrids sold in Japan. “Japan is a key market for myFC, and as of today,

Advania is investing in the developing world's superstar, Atlassian

Advania became one of Atlassian's Swedish Solution Partners in the spring of 2018. As of October 2018, Advania is a Silver Solution Partner to the Australian software company with products like Jira, Confluence and Jira Service Desk in its portfolio."Atlassian has really impressed the developing world in recent years, and we feel extremely excited for their products in the Nordic market. Already today, many of our customers use their products. As we now strengthen the collaboration with Atlassian, we expand our skills and offerings in the development segment, and software development. We

Share buy-backs in Telia Company during week 48 2018

During the period 26 November 2018 – 30 November 2018, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 1 840 000 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back programme that Telia Company announced on 20 April 2018. The share buy-back programme, which runs between 23 April 2018 and 22 March 2019, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period 26 November

Eniro has reached an agreement with PRI

Eniro AB (publ) (”Eniro”) has pledged funds on a bank account in the amount of approximately SEK 200 million as collateral for the group’s commitments towards Försäkringsbolaget PRI Pensionsgaranti, ömsesidigt (”PRI”). As previously announced, the collateral would have been increased with SEK 7 million to SEK 207 million as per 30 June 2018. In connection with, and taking into consideration Eniro’s refinancing through the bond loan issued by Eniro on 25 September 2018, PRI confirmed to Eniro that PRI may be willing to, under certain conditions, give a respite with an increase of the

Höegh LNG : HMLP phantom unit vesting - mandatory notification of trade

Hamilton, Bermuda, 3 December, 2018 - Reference is made to the stock exchange notice by Höegh LNG Holdings Ltd. ("Höegh LNG") dated 6 June 2016 regarding the award of 53,568 phantom units in Höegh LNG Partners LP ("HMLP") by Höegh LNG to senior management and key employees of Höegh LNG AS. On 30 November 2018, 17,856 of the phantom units vested, all of which will be settled in cash.  Reference is further made to the stock exchange notice by Höegh LNG dated 6 June 2016 regarding the award of 21,500 phantom units by the board of directors of HMLP to Richard Tyrrell. On 30 November 2018, 7,

Höegh LNG : Appointment of new CFO

Hamilton, Bermuda, 3 December 2018 - Höegh LNG Holdings Ltd. (the “company”) refers to the stock exchange notice dated 14 September 2018 regarding changes to the group executive team of Höegh LNG AS, the management services company that provides services to Höegh LNG Holdings Ltd. and its subsidiaries (“Höegh LNG”). The company announced today that Mr. Håvard Furu is appointed as new Chief Financial Officer (CFO) of Höegh LNG AS effective 1 March 2019. The interim CFO, Steffen Føreid, will step down effective 1 March 2019 and will from then continue in his role as Chief Executive Officer

Gaming Innovation Group: Capital Markets Day 4 Dec 2018 available via live streaming

Gaming Innovation Group Inc. (GiG) invites analysts, investors and media to its Capital Markets Day on 4 December 2018, at Berns, room Kammarsalen, Berzelii Park, Stockholm, Sweden. The presentation starts at 13:30 CET and is expexted to end at 16:45 and will be held in English, registration from 13:00 CET. If you would like attend in person, please do not hesitate to register by sending an email to cmd@gig.com If you are not able to attend, the presention can also be followed via live streaming by using the following link: GiG Capital Markets Day 

BerGenBio reports 43% response rate with bemcentinib monotherapy in AXL positive R/R AML/MDS patients at ASH

· 43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14) · Phase II trial continues in combination with chemotherapeutics in first line AML · Bemcentinib with decitabine cohort has completed recruitment, data will be submitted for presentation at upcoming medical congressBergen, Norway, 3 Dec 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, today announced that it presented a

Nordic Nanovector: Single administration Betalutin® is effective and well-tolerated in R/R iNHL patients: 6 month follow-up data presented at ASH

· Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin’s lymphoma (iNHL) · Highly active in follicular lymphoma (FL) patients with ≥2 prior therapies (n=37) (ORR 70% CR 32%), and rituximab-refractory FL (n=21) (ORR 62% CR 19%) · Durable responses, especially for patients with a CR (20.7 months) · Promising response rates (ORR and CR) for dosing regimens being evaluated in pivotal Phase 2b PARADIGME study · Well tolerated with predictable and manageable safety profile · Conference call/audio cast to discuss results to

Enzymatica AB: Enzymatica raises SEK 98.7 million in completed share issue

Press release December 2, 2018 NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEELAND OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW. Enzymatica raises SEK 98.7 million in completed share issue On November 28, 2018, the subscription period in the rights issue of shares, which Enzymatica AB (publ) ("Enzymatica" or the "Company") published on

Anders Lönner, chairman of the Board Karo Pharma AB, has suddenly passed away

“It is with great regret and sadness we announce this very tragic and unexpected information”, says the Board of Directors, Karo Pharma.“Anders Lönner has suddenly and unexpected passed away. Our thoughts go to his family and those closest to him”. Anders Lönner joined Karo Pharma as Executive Chairman of the Board in 2014. Since then the company has experienced strong and profitable growth. With his longstanding and deep knowledge Anders has influenced the pharmaceutical industry in Sweden in an extraordinary way. This is evident from all the special acknowledgements that Anders

Finnish blood testing scale-up and health service provider introduce healthcare for the 21 st century – connecting molecular medicine with lifestyle habits

The new service, Virta 360, connects a person’s current state of physical health with their lifestyle. The service helps people to understand their current risks for chronic diseases and identifies potential areas where they can improve their wellbeing.Pioneering blood testing company, Nighti ngale Health , and Finnish wellbeing service provider Aava Virta ,  have launched Virta  360 

Oncopeptides presents first interim data from the ongoing combination trial ANCHOR with melflufen at the 60th American Society of Hematology Meeting

Stockholm – December 1, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today a presentation of the first interim data with melflufen (Ygalo®) from the ongoing phase I/II study ANCHOR at the 60th ASH meeting in San Diego, California, USA.Overall conclusions · The combinations of melflufen and dexamethasone (dex) with either bortezomib or daratumumab in relapsed-refractory multiple myeloma (RRMM) patients are well tolerated · No dose limiting toxicity has been observed at the melflufen 30 and 40 mg dose levels in either regimens. The 40 mg dose level is still recruiting

At ASH, extended half-life therapies Elocta® and Alprolix® demonstrate proven efficacy and well-characterised safety over four years

ASPIRE and B-YOND extension studies show no inhibitor development and consistently low annualised bleeding rates in study participants over four years with Elocta and Alprolix, respectively. Swedish Orphan Biovitrum AB (publ)  (Sobi™) and Bioverativ Inc ., a Sanofi-company, today announced the final results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended half-life factor therapies in haemophilia. The data from both studies confirm the established safety and sustained efficacy of Elocta® (

NGEx Share Capital and Voting Rights Update

Vancouver, November 30, 2018 /CNW/ - NGEx Resources Inc. ("NGEx" or the “Company”) (TSX: NGQ; NASDAQ Stockholm: NGQ), reports the following share capital and voting rights update in accordance with the Swedish Financial Instruments Trading Act. As a result of the issuance of 250,000 common shares pursuant to the exercise of stock options pursuant to the Company’s Stock Option Plan, the number of issued and outstanding shares of the Company has increased to 227,909,153 common shares with voting rights as at November 30, 2018. Additional Information  This information is information

Updated Share Capital and Voting Rights for BlackPearl

CALGARY, ALBERTA, Nov. 30, 2018 /CNW/ - BlackPearl Resources Inc. ("BlackPearl" or the "Company") (TSX: PXX) (NASDAQ Stockholm: PXXS) reports the following, in accordance with the Swedish Financial Instruments Trading Act: As a result of the exercise of stock options, as at November 30, 2018, the number of issued and outstanding shares of the Company is 337,688,841 common shares with voting rights. The information in this release is subject to the disclosure requirements of BlackPearl Resources Inc. under the Swedish Financial Instruments Trading Act. The information was submitted for

Nine months 2018 results

Revenues for the period January to September 2018 were USD 501 million and increased by 31% as compared to the same period last year. Total loss for the period was USD 33.6 million compared to USD 13.5 million loss for the same period last year. · Loss for the period USD 33.6 million · EBITDA USD -18.9 million, as compared to USD 8.8 million last year · Equity ratio 7% at the end of September The Board of Directors and the Chief Executive Officer draw attention to notes 3 and 11 that accompany these financial statements which contain information on events after the reporting

New Number of Shares and Votes in Tobii

The number of shares and votes in Tobii AB has increased by 1,330,310 as a result of exercise of warrants in accordance with the company’s incentive programs. Today, the last trading day of the month, there are in total 98,904,665 shares and votes in the company. After the increase, the share capital amounts to SEK 717,744.57. The increase in the number of shares is due to the exercise of warrants in accordance with the Company's incentive programs. This information is information that Tobii is obliged to make public pursuant to the Financial Instruments Trading Act. The information

Borr Drilling Limited (BDRILL) – Purchase of own shares

Borr Drilling Limited (the “Company”) has today purchased 400,000 of its own shares at an average price of NOK 27.1632 per share. The share purchase has been carried out in connection with the share repurchase program announced by the Company on 28 August 2018. After this transaction the Company holds 5,698,572 of its own shares in treasury. 30 November 2018 Hamilton, Bermuda This information is subject to disclosure requirements pursuant to Sections 4-2 and 5-12 of the Norwegian Securities Trading Act.

4th Quarter Results

ROYAL BANK OF CANADA 2018 ANNUAL REPORT (PART II OF II) To view the 2018 Annual Report in PDF, please click on the link below: http://www.rns-pdf.londonstockexchange.com/rns/1353J_1-2018-11-30.pdf Caution regarding forward-looking statements From time to time, we make written or oral forward-looking statements within the meaning of certain securities laws, including the "safe harbour" provisions of the United States Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation. We may make forward-looking statements in this 2018 Annual

4th Quarter Results

ROYAL BANK OF CANADA 2018 ANNUAL REPORT (PART I OF II) To view the 2018 Annual Report in PDF, please click on the link below: http://www.rns-pdf.londonstockexchange.com/rns/1331J_1-2018-11-30.pdf  Management's Discussion and Analysis Management's Discussion and Analysis (MD&A) is provided to enable a reader toassess our results of operations and financial condition for the fiscal yearended October 31, 2018, compared to the preceding fiscal year. This MD&Ashould be read in conjunction with our 2018 Annual Consolidated FinancialStatements and related notes and is dated

There are no items matching the current filter
There are no more items matching the current filter
Back to top